Here are four takeaways:
1. The trial is being conducted under a special protocol assessment with the FDA.
2. The trial is designed to evaluate the safety and efficacy of NeoCart as a first-line therapy for full thickness knee cartilage defects in adults.
3. NeoCart is a cartilage-like, tissue engineered implant created from a patient’s own cartilage cells.
4. Histogenics is a regenerative medicine company focused on developing and commercializing products in the musculoskeletal market.
More articles on devices:
K2M Group Holdings shares hit 52-week low: 5 notes
Medovex obtains reimbursement for its DenerveX Facet Joint Syndrome Treatment: 4 takeaways
Global non-fusion spinal device market to grow – 3 points
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
